The efficacy of this combination could even be enhanced by prior transient exposure to BCL-xL inhibitors which promote the binding of pro-apoptotic proteins (in particular BIM) from BCL-xL to MCL-1 and by this way augment the tumor MCL-1 dependency [60]. This evidence concerns the gene BCL2L1 and neoplasm.